Previous 10 | Next 10 |
home / stock / mvmdf / mvmdf news
Compared to traditional methods, Soluvec™ demonstrated significant enhancement in Ivermectin solubilization and bioavailability. Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a lead...
TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce that Mountain Valley MD Inc. (“Mountain Valley”) has entered into a license ...
TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), an early-stage biotech business centered around the implementation, licensing and reselling of key technologie...
An early-stage biotech business centered around the implementation, licensing and reselling of key technologies and formulations, Mountain Valley MD ( OTCQB:MVMDF ) announced that Dr. Azhar Rana, the company’s Chief Medical Officer, will be transitioning to an advisory ca...
TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), an early-stage biotech business centered around the implementation, licensing and reselling of key technologies...
TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) announces that it will redeem all issued and outstanding Class “B” Non-Voting Shares (the “...
TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current commercialization strategy. MVMD ...
TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to announce the commencement of commercial sales and marketing of Agrarius, a certified organi...
Mountain Valley MD Holdings (MVMD) (OTCQX: MVMDF) has announced the successful completion of its pre-clinical pharmacokinetic study. The pre-clinical pharmacokinetic study – IM032, was done on male beagle dogs by comparing the intramuscular (IM) and subcutaneous (SC) do...
TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to announce the successful completion of its pre-clinical pharmacokinetic study - IM032 - in ma...
News, Short Squeeze, Breakout and More Instantly...
Mountain Valley MD Holdings Inc Company Name:
MVMDF Stock Symbol:
OTCMKTS Market:
Mountain Valley MD Holdings Inc Website:
Mountain Valley MD Holdings Inc (MVMDF) is expected to report for Q2 2022
Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce that it has executed an Amended and Restated Supply and License Agreement (the “ Agreement ”) with Agrarius Corp. (&...
Mountain Valley MD Holdings Inc. (the “ Company ” or “ MVMD ”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a broad business update of its progress across its three core lines of business: Nutraceuticals - novel innovations through t...